Cargando…
Quantitative impact of pre‐analytical process on plasma uracil when testing for dihydropyrimidine dehydrogenase deficiency
AIMS: Determining dihydropyrimidine dehydrogenase (DPD) activity by measuring patient's uracil (U) plasma concentration is mandatory before fluoropyrimidine (FP) administration in France. In this study, we aimed to refine the pre‐analytical recommendations for determining U and dihydrouracil (U...
Autores principales: | Maillard, Maud, Launay, Manon, Royer, Bernard, Guitton, Jérôme, Gautier‐Veyret, Elodie, Broutin, Sophie, Tron, Camille, Le Louedec, Félicien, Ciccolini, Joseph, Richard, Damien, Alarcan, Hugo, Haufroid, Vincent, Tafzi, Naïma, Schmitt, Antonin, Etienne‐Grimaldi, Marie‐Christine, Narjoz, Céline, Thomas, Fabienne |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10092089/ https://www.ncbi.nlm.nih.gov/pubmed/36104927 http://dx.doi.org/10.1111/bcp.15536 |
Ejemplares similares
-
Impact of renal impairment on dihydropyrimidine dehydrogenase (DPD) phenotyping
por: Royer, B., et al.
Publicado: (2023) -
Food‐effect study on uracil and dihydrouracil plasma levels as marker for dihydropyrimidine dehydrogenase activity in human volunteers
por: Henricks, Linda M., et al.
Publicado: (2018) -
Implementation of dihydropyrimidine dehydrogenase deficiency testing in Europe
por: de With, M., et al.
Publicado: (2023) -
Dihydropyrimidine Dehydrogenase Phenotyping Using Pretreatment Uracil: A Note of Caution Based on a Large Prospective Clinical Study
por: de With, Mirjam, et al.
Publicado: (2022) -
Cancer Immunotherapy Dosing: A Pharmacokinetic/Pharmacodynamic Perspective
por: Le Louedec, Félicien, et al.
Publicado: (2020)